Skip to content
MRNA·Nasdaq·US

Moderna

Moderna is a pioneer and leader in mRNA medicine that develops vaccine and therapeutic candidates across infectious disease, oncology, and rare disease. The company currently markets three commercial products—Spikevax, mNEXSPIKE, and mRESVIA—and generated total revenue of $1.9 billion in 2025, largely from sales of its COVID vaccines.

Source: SEC 10-K Feb 20, 2026

Recent Activity

Updated Oct 24, 2026
–Moderna and Merck's personalized melanoma vaccine combined with Keytruda cut the risk of relapse or death by 42% in a late-stage study of melanoma patients.
–Moderna and Merck are engaging with regulators, with a potential US regulatory submission aimed at supporting a 2027 launch timeline.
–Partial, confidential data on the melanoma vaccine leaked before the full results were released.

Past updates are part of the Pro plan.

Thematic Position

MRNA

Relationship Groups

Suppliers3
Partners7
Licensing3
Competitors13

Relationship details are part of the Pro plan.

Recent Discoveries

Recent discoveries are part of the Pro plan.

Ended Relationships

3 ended relationships · Ended relationships are part of the Pro plan.

Management Perspective on Regulatory & Geopolitical Developments

compulsory licensingmarch-in rights
Bayh-Dole Act march-in rights could force compulsory licensing of Moderna inventions
SEC 10-KFeb 20, 2026

The full regulatory passage is part of the Pro plan.

8 more · Regulatory and geopolitical insights are part of the Pro plan.